The European Commission (EC) has made 1 billion euro available for new projects involving micro and nanotechnology.
The European Commission (EC) has made 1 billion euro available for new projects involving micro and nanotechnology. The amount will come from the EC's Information Communications Technology and Nanoscience, Nanotechnology, Materials and New Production Processes (NMP) funds as part of the Framework Programme 7 (FP7).
"European FP7 enables organizations, through collaborative R&D, to access new partners, skills and knowledge in the development of their future products and services," Alastair McGibbon, the UK FP7 national contact point for NMP, said in a statement.
The UK's Nanotechnology Knowledge Transfer Network (NanoKTN) is very supportive of the funds, which could provide a boost for pharma. "Nanotechnology is being increasingly used by the pharmaceutical industry in two areas: drug discovery, where smaller assay volumes are used and greater information is obtained; and formulation, where nanocarriers improve bioavailability and efficacy," Mike Fisher, BioNano Theme Manager at NanoKTN, explained to Pharmaceutical Technology Europe. "Adoption has been relatively slow, but this is because companies need to see a clear path to market."
Several calls for funding have now been scheduled during the next 9 months. The first deadline is 8 December 2009. According to NanoKTN, the UK, as well as the rest of Europe, could stand to benefit from this funding. "Nanotechnologies and microtechnologies are being recognized as important means of wealth and job creation for the UK and Europe, and successful development and uptake of new technology is central to the UK's wealth creation in the next 20 years," Alec Reader, Director of NanoKTN, said in the press statement.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.